MedTrace Logo

Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability

NCT02603822 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-06-04

No results posted yet for this study

Summary

The investigators' overall objective with this study is to determine performance characteristics of small intestine permeability measurement using 13C mannitol and 12C (regular) mannitol.

Conditions

  • Impaired Small Intestinal Permeability

Interventions

DIETARY_SUPPLEMENT

12C mannitol

12C mannitol 100 mg

DRUG

Indomethacin

Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.

DIETARY_SUPPLEMENT

13C mannitol

13C mannitol 100 mg

DIETARY_SUPPLEMENT

Lactulose

lactulose 1 g

Sponsors & Collaborators

Principal Investigators

  • Madhusudan Grover, MBBS · Mayo Clinic

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-07-17
Completion
2018-07-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02603822 on ClinicalTrials.gov